Meningococcal serogroup B vaccines: will they live up to expectations?
- PMID: 21604975
- PMCID: PMC3985070
- DOI: 10.1586/erv.11.41
Meningococcal serogroup B vaccines: will they live up to expectations?
Similar articles
-
A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.Expert Rev Vaccines. 2011 May;10(5):575-88. doi: 10.1586/erv.11.32. Expert Rev Vaccines. 2011. PMID: 21604979 Review.
-
Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.Expert Rev Vaccines. 2010 Oct;9(10):1203-17. doi: 10.1586/erv.10.116. Expert Rev Vaccines. 2010. PMID: 20923270 Review.
-
Reverse vaccinology--in search of a genome-derived meningococcal vaccine.Vaccine. 2006 Apr 12;24 Suppl 2:S2-11-2. doi: 10.1016/j.vaccine.2005.01.103. Vaccine. 2006. PMID: 16823908 Review.
-
Neisseria meningitidis serogroup B: laboratory correlates of protection.FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. doi: 10.1111/j.1574-695X.2002.tb00608.x. FEMS Immunol Med Microbiol. 2002. PMID: 12381458 Review.
-
Recent developments in vaccines to prevent meningococcal serogroup B infections.Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Curr Opin Mol Ther. 2003. PMID: 12669468 Review.
Cited by
-
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.Drugs. 2014 Jan;74(1):15-30. doi: 10.1007/s40265-013-0155-7. Drugs. 2014. PMID: 24338083 Free PMC article. Review.
-
Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Feb 1;68(Pt 2):231-5. doi: 10.1107/S1744309111056028. Epub 2012 Jan 27. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012. PMID: 22298007 Free PMC article.
-
Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.PLoS One. 2013;8(1):e54314. doi: 10.1371/journal.pone.0054314. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372704 Free PMC article.
-
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.Hum Vaccin Immunother. 2013 Nov;9(11):2304-10. doi: 10.4161/hv.25505. Epub 2013 Jun 28. Hum Vaccin Immunother. 2013. PMID: 23811804 Free PMC article.
-
Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):17871-5. doi: 10.1073/pnas.1114489108. Epub 2011 Oct 24. Proc Natl Acad Sci U S A. 2011. PMID: 22025709 Free PMC article.
References
-
- Wong SH, Lennon DR, Jackson CM, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J. 2009;28:385–390. - PubMed
-
- Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 2010;51:1127–1137. - PubMed
-
- Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine. 2009;27:2794–2803. - PubMed
Website
-
- Neisseria factor H binding protein sequence typing. http://pubmlst.org/neisseria/fHbp/
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical